FDA takes first step in possible reversal of ban on some peptides The Washington Post FDA to weigh easing limits on unproven peptides FDA Updates Safety Label for Capecitabine and 5 FU for Risks Associated With DPD Deficiency Oncology Nursing Society BPC 157: Experimental Peptide Creates Risk for Athletes Access to Unapproved Drugs: FDA Policies on Compassionate Use and Emergency Use Authorization EveryCRSReport.com